Notably, copy number changes for ERBB2 have been shown to strongly correlate with overexpression levels detected by IHC, and actionable ERBB2 mutations are now commonly included in NGS panels for CGP of gastrointestinal tumors [12,13]. Here, ERBB2 is linked to digestive system neoplasm.